Clinicopathologic and Demographic Evaluation of Triple-Negative Breast Cancer Patients among a Turkish Patient Population: a Single Center Experience

  • Somali, Isil (Department of Medical Oncology, Institute of Oncology, Dokuz Eylul University Medical Faculty) ;
  • Ustaoglu, Bahar Yakut (Department of Internal Medicine, Tepecik Training and Research Hospital) ;
  • Tarhan, Mustafa Oktay (Department of Medical Oncology, Ataturk Training and Research Hospital, Izmir Katip Celebi University) ;
  • Yigit, Seyran Ceri (Department of Pathology, Ataturk Training and Research Hospital, Izmir Katip Celebi University) ;
  • Demir, Lutfiye (Department of Medical Oncology, Ataturk Training and Research Hospital, Izmir Katip Celebi University) ;
  • Ellidokuz, Hulya (Department of Preventive Oncology, Institute of Oncology, Dokuz Eylul University Medical Faculty) ;
  • Erten, Cigdem (Department of Medical Oncology, Ataturk Training and Research Hospital, Izmir Katip Celebi University) ;
  • Alacacioglu, Ahmet (Department of Medical Oncology, Ataturk Training and Research Hospital, Izmir Katip Celebi University)
  • Published : 2013.10.30


Background: To evaluate the clinicopathologic and demographic characteristics of triple-negative breast cancer (TNBC) patients and to determine differences from non-triple-negative cases. Materials and Methods: A detailed review of the medical records of 882 breast cancer (BC) patients was conducted to obtain information regarding age, menopausal status, height and weight at the time of diagnosis, presence of diabetes or hypertension, and pathologic characteristics of the tumor (tumor size, lymph node status, histologic grade, ER status, PR status, HER2 status, p53 mutation). Body mass index (BMI) was calculated and a value of ${\geq}30$ was considered as indicative of obesity. Results: 14.9% (n=132) of the patients had TNBC. There was no difference among the patients in terms of median age, comorbid conditions and menopausal status. The proportion of medullary, tubular and mucinous carcinomas was significantly higher (15.9%) in the triple-negative (TN) group, while invasive lobular histology was more frequent (8.2%) among non-triple negative (NTN) cases (p<0.001). Grade 3 (G3) tumors were more frequent in the triple-negative group (p<0.001). The rate of p53 mutation was 44.3% in TN tumors versus 28.2% in the NTN group (p<0.001). The two groups were similar in terms of LN metastasis. In the NTN group, the rate of patients with BMI ${\geq}30$ was 53% among postmenopausal patients, while it was 36% among premenopausal women, and the difference was statistically significant (p<0.001). No significant difference was observed in terms of BMI between postmenopausal and premenopausal patients in the TN group (p=0.08). Conclusions: TNBC rates and clinicopathologic characteristics of the Turkish patient population were consistent with the data from Europe and America. However, no relationship between obesity and TNBC was observed in our study. The association between TNBC and obesity needs to be evaluated in a larger patient population.


Breast cancer;triple;negative tumors;non-triple-negative breast cancer;BMI


  1. Bulun SE, Chen D, Moy I, Brooks DC, Zhao H (2012). Aromatase, breast cancer and obesity: a complex interaction. Trends Endocrinol Metab, 23, 83-9.
  2. Aksoy S, Dizdar O, Harputluoglu H, Altundag K (2007). Demographic, clinical, and pathological characteristics of Turkish triple-negative breast cancer patients: single center experience. Ann Oncol, 18, 1904-6.
  3. Anders C, Carey LA (2008). Understanding and treating triple-negative breast cancer. Oncology (Williston Park), 22, 1233-9.
  4. Bidard FC, Conforti R, Boulet T, et al (2007). Does triple-negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 'triple negative'breast cancers. Ann Oncol, 18, 1285-6.
  5. Crabb SJ, Cheang MC, Leung S, et al (2008). Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer. Clin Breast Cancer, 8, 249-56.
  6. Daling JR, Malone KE, Doody DR, et al (2001). Relation of body mass index to tumor markers and survival among young women with invasive ductal breast carcinoma. Cancer, 92, 720-9.<720::AID-CNCR1375>3.0.CO;2-T
  7. Fitzgibbons PL, Page DL, Weaver D, et al (2000). Prognostic factors in breast cancer. College of American pathologists consensus statement 1999. Arch Pathol Lab Med, 124, 966-78.
  8. De Onis M, Onyango AW, Borghi E, et al (2007). Development of a WHO growth reference for school-aged children and adolescents. Bull WHO, 85, 660-7.
  9. Durnay A, Feugeas JP, Wittmer E, et al (2013). Distinct tumor protein p53 mutants in breast cancer subgroups. Int J Cancer, 132, 1227-31.
  10. Federico A, Morgillo F, Tuccillo C, Ciardiello F, Loguercio C (2007). Chronic inflammation and oxidative stress in human carcinogenesis. Int J Cancer, 121, 2381-6.
  11. Foulkes WD, Smith IE, Reis-Filho (2010). Triple-negative breast cancer. N Engl J Med, 363, 1938-48.
  12. Lahmann PH, Hoffmann K, Allen N, et al (2004). Body size and breast cancer risk: findings from the European prospective investigation into cancer and nutrition (EPIC). Int J Cancer, 111, 762-71.
  13. Lara-Medina F, Pe'rez-Sa'nchez V, Saavedra-Pe'rez D, et al (2011). Triple-negative breast cancer in hispanic patients. Cancer, 117, 3658-69.
  14. Lin NU, Vanderplas A, Hughes ME, et al (2012). Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the national comprehensive cancer network. Cancer, 118, 5463-72.
  15. Millikan RC, Newman B, Tse CK, et al (2008). Epidemiology of basal-like breast cancer. Breast Cancer Res Treat, 109, 123-39.
  16. Nielsen TO, Hsu FD, Jensen K, et al (2004). Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res, 10, 5367-74.
  17. Phipps AI, Chlebowski RT, Prentice R, et al (2011). Body size, physical activity, and risk of triple-negative and estrogen receptor-positive breast cancer. Cancer Epidemiol Biomarkers Prev, 20, 454-63.
  18. Oakman C, Viale G, Di Leo A (2010). Management of triple negative breast cancer. The Breast, 19, 312-21.
  19. Oken MM, Creech RH, Tormey DC, et al (1982). Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol, 5, 649-55.
  20. Perou CM, Sorlie T, Eisen MB, et al (2000). Molecular portraits of human breast tumours. Nature, 406, 747-52.
  21. Pierobon M, Frankenfeld CL (2013). Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis. Breast Cancer Res Treat, 137, 307-14.
  22. Rakha EA, Reis-Filho JS, Ellis IO (2008). Basal-like breast cancer: a critical review. J Clin Oncol, 26, 2568-81.
  23. Rose DP, Vona-Davis L (2010). Interaction between menopausal status and obesity in affecting breast cancer risk. Maturitas, 66, 33-8.
  24. Sastre-Garau X, Jouve M, Asselain B, et al (1996). Infiltrating lobular carcinoma of the breast. Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns. Cancer, 77, 113-20.<113::AID-CNCR19>3.0.CO;2-8
  25. Sorlie T, Perou CM, Tibshirani R, et al (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA, 98, 10869-74.
  26. Suzuki R, Orsini N, Saji S, Key TJ, Wolk A (2009). Body weight and incidence of breast cancer defined by estrogen and progesterone receptor status: a meta-analysis. Int J Cancer, 124, 698-712.
  27. Trivers KF, Lund MJ, Porter PL, et al (2009). The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control, 20, 1071-82.
  28. Vona-Davis L, Rose DP (2007). Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocr Relat Cancer, 14, 189-206.
  29. Yamamoto Y, Iwase H (2010). Clinicopathological features and treatment strategy for triple-negative breast cancer. Int J Clin Oncol, 15, 341-51.

Cited by

  1. Associations Between Mammography and Ultrasound Imaging Features and Molecular Characteristics of Triple-negative Breast Cancer vol.15, pp.8, 2014,
  2. Clinicopathology Figures and Long-term Effects of Tamoxifen Plus Radiation on Survival of Women with Invasive Ductal Carcinoma and Triple Negative Breast Cancer vol.16, pp.12, 2015,
  3. Epidemiological Study of Triple-Negative Breast Cancer Patients in North Indian Population: a Hospital-Based Study vol.8, pp.3, 2017,